AP NEWS

Third Rock Ventures Names Reid Huber, Ph.D., as Partner

November 27, 2018

BOSTON--(BUSINESS WIRE)--Nov 27, 2018--Third Rock Ventures LLC today announced Reid Huber, Ph.D., is joining the firm as a partner. Dr. Huber brings 20 years of leadership and experience to the role. He joins the firm from Incyte where he was a member of the founding scientific team and most recently served as the company’s Chief Scientific Officer.

“I am very excited to be joining Third Rock. Having interacted with the team over the years, I have been consistently impressed with their collaborative approach, desire to discover transformative solutions to important unmet medical needs, and focus on the metric that matters most: making a difference in the lives of patients,” said Dr. Huber. “I look forward to contributing to the firm’s ongoing efforts and its long-term success as we continue to advance important science to build sustainable companies.”

“We believe without a doubt that people are our most important asset and we are thrilled to welcome Reid as a new partner to the team,” said Robert Tepper, M.D., partner at Third Rock. “Reid’s extensive R&D leadership combined with his strategic and operations experience will be a tremendous asset as we continue to work collectively to discover, launch and build new companies. We look forward to leveraging his broad experience from early drug discovery through commercial execution as we translate the unprecedented level of innovation emerging from academia and industry to our company creation efforts.”

Dr. Huber comes to Third Rock from Incyte, which he joined in 2002 and most recently served as Executive Vice President and Chief Scientific Officer. At Incyte, Dr. Huber held roles of increasing responsibility across multiple therapeutic areas in both drug discovery and clinical development. In 2011, Dr. Huber assumed responsibility for the company’s research activities as Senior Vice President, Discovery Biology. Before joining Incyte, Dr. Huber held scientific research positions at DuPont and Bristol-Myers Squibb from 1998 to 2002. Dr. Huber received his Ph.D. in molecular genetics from the Washington University School of Medicine and held predoctoral and postdoctoral fellowships at the National Institutes of Health.

About Third Rock Ventures

Third Rock Ventures is a leading healthcare venture firm focused on disruptive areas of science and medicine to discover, launch and build companies that make a dramatic difference in people’s lives. By combining our team’s scientific vision, strategic leadership, operational expertise and innovative deal-making capabilities, we nurture bold ideas that translate into successful business enterprises. Recognizing that the best way to create value for our investors is to create value for patients, our companies are built on a solid foundation of science, medicine, people and business strategy. For more information, please visit www.thirdrockventures.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20181127005201/en/

CONTACT: Cynthia Clayton

Third Rock Ventures

617-585-2010

cclayton@thirdrockventures.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: HEALTH OTHER HEALTH GENERAL HEALTH

SOURCE: Third Rock Ventures

Copyright Business Wire 2018.

PUB: 11/27/2018 07:45 AM/DISC: 11/27/2018 07:45 AM

http://www.businesswire.com/news/home/20181127005201/en

AP RADIO
Update hourly